The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The facility will manufacture its Herceptin biosimilar, Tuznue
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Subscribe To Our Newsletter & Stay Updated
